 | • レポートコード：D0804-14630 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、103ページ • 納品方法：Eメール • 産業分類：医療機器・医療消耗品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、急性骨髄性白血病の世界市場を広く調査・分析し、今後の市場展望をまとめております。急性骨髄性白血病の種類別市場規模（化学療法、標的療法）、用途別市場規模（大人、子供）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：GSK、Eisai、Bristol-Myers Squibb、Novartis、Daiichi Sankyo、Roche、Sunesis Pharmaceuticals、Clavis Pharma ASA、Celgene、Teva ・地域別グローバル市場分析 2015年-2020年 ・急性骨髄性白血病の北米市場（アメリカ、カナダ、メキシコ） ・急性骨髄性白血病のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・急性骨髄性白血病のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・急性骨髄性白血病の南米市場（ブラジル、アルゼンチン） ・急性骨髄性白血病の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：化学療法、標的療法 ・用途別分析：大人、子供 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Acute Myeloid Leukemia market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Acute Myeloid Leukemia sales will be xx in 2020 from Acute Myeloid Leukemia million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Acute Myeloid Leukemia market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Acute Myeloid Leukemia industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Acute Myeloid Leukemia and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Acute Myeloid Leukemia market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Acute Myeloid Leukemia market has been segmented into:
Chemotherapy
Targeted Therapy
By Application, Acute Myeloid Leukemia has been segmented into:
Adults
Children
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Acute Myeloid Leukemia market presented in the report. This section sheds light on the sales growth of different regional and country-level Acute Myeloid Leukemia markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Acute Myeloid Leukemia market.
The report offers in-depth assessment of the growth and other aspects of the Acute Myeloid Leukemia market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Acute Myeloid Leukemia Market Share Analysis
Acute Myeloid Leukemia competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Acute Myeloid Leukemia sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Acute Myeloid Leukemia sales, revenue and market share for each player covered in this report.
The major players covered in Acute Myeloid Leukemia are:
GSK
Eisai
Bristol-Myers Squibb
Novartis
Daiichi Sankyo
Roche
Sunesis Pharmaceuticals
Clavis Pharma ASA
Celgene
Teva
Among other players domestic and global, Acute Myeloid Leukemia market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Acute Myeloid Leukemia Market Overview
1.1 Product Overview and Scope of Acute Myeloid Leukemia
1.2 Classification of Acute Myeloid Leukemia by Type
1.2.1 Global Acute Myeloid Leukemia Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Acute Myeloid Leukemia Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Targeted Therapy
1.3 Global Acute Myeloid Leukemia Market by Application
1.3.1 Overview: Global Acute Myeloid Leukemia Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Adults
1.3.3 Children
1.4 Global Acute Myeloid Leukemia Market by Regions
1.4.1 Global Acute Myeloid Leukemia Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Acute Myeloid Leukemia (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Acute Myeloid Leukemia Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Acute Myeloid Leukemia Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Acute Myeloid Leukemia Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Acute Myeloid Leukemia Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Acute Myeloid Leukemia Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Acute Myeloid Leukemia Industry Impact
1.5.1 COVID-19 Potential Implications for the Acute Myeloid Leukemia
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Acute Myeloid Leukemia
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 GSK SWOT Analysis
2.1.4 GSK Product and Services
2.1.5 GSK Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
2.2 Eisai
2.2.1 Eisai Details
2.2.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Eisai SWOT Analysis
2.2.4 Eisai Product and Services
2.2.5 Eisai Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Bristol-Myers Squibb SWOT Analysis
2.3.4 Bristol-Myers Squibb Product and Services
2.3.5 Bristol-Myers Squibb Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
2.5 Daiichi Sankyo
2.5.1 Daiichi Sankyo Details
2.5.2 Daiichi Sankyo Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Daiichi Sankyo SWOT Analysis
2.5.4 Daiichi Sankyo Product and Services
2.5.5 Daiichi Sankyo Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Roche Product and Services
2.6.4 Roche Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
2.7 Sunesis Pharmaceuticals
2.7.1 Sunesis Pharmaceuticals Details
2.7.2 Sunesis Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Sunesis Pharmaceuticals Product and Services
2.7.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
2.8 Clavis Pharma ASA
2.8.1 Clavis Pharma ASA Details
2.8.2 Clavis Pharma ASA Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Clavis Pharma ASA Product and Services
2.8.4 Clavis Pharma ASA Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
2.9 Celgene
2.9.1 Celgene Details
2.9.2 Celgene Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Celgene Product and Services
2.9.4 Celgene Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
2.10 Teva
2.10.1 Teva Details
2.10.2 Teva Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Teva Product and Services
2.10.4 Teva Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Acute Myeloid Leukemia Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Acute Myeloid Leukemia Players Market Share
3.2.2 Top 10 Acute Myeloid Leukemia Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Acute Myeloid Leukemia Revenue and Market Share by Regions
4.2 North America Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
4.3 Europe Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
4.5 South America Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
5 North America Acute Myeloid Leukemia Revenue by Countries
5.1 North America Acute Myeloid Leukemia Revenue by Countries (2015-2020)
5.2 USA Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
5.3 Canada Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
5.4 Mexico Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
6 Europe Acute Myeloid Leukemia Revenue by Countries
6.1 Europe Acute Myeloid Leukemia Revenue by Countries (2015-2020)
6.2 Germany Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
6.3 UK Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
6.4 France Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
6.5 Russia Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
6.6 Italy Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Acute Myeloid Leukemia Revenue by Countries
7.1 Asia-Pacific Acute Myeloid Leukemia Revenue by Countries (2015-2020)
7.2 China Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
7.3 Japan Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
7.4 Korea Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
7.5 India Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
8 South America Acute Myeloid Leukemia Revenue by Countries
8.1 South America Acute Myeloid Leukemia Revenue by Countries (2015-2020)
8.2 Brazil Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
8.3 Argentina Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Acute Myeloid Leukemia by Countries
9.1 Middle East & Africa Acute Myeloid Leukemia Revenue by Countries (2015-2020)
9.2 Saudi Arabia Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
9.3 UAE Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
9.4 Egypt Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
9.5 South Africa Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Acute Myeloid Leukemia Revenue and Market Share by Type (2015-2020)
10.2 Global Acute Myeloid Leukemia Market Forecast by Type (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Targeted Therapy Revenue Growth Rate (2015-2025)
11 Global Acute Myeloid Leukemia Market Segment by Application
11.1 Global Acute Myeloid Leukemia Revenue Market Share by Application (2015-2020)
11.2 Acute Myeloid Leukemia Market Forecast by Application (2019-2024)
11.3 Adults Revenue Growth (2015-2020)
11.4 Children Revenue Growth (2015-2020)
12 Global Acute Myeloid Leukemia Market Size Forecast (2021-2025)
12.1 Global Acute Myeloid Leukemia Market Size Forecast (2021-2025)
12.2 Global Acute Myeloid Leukemia Market Forecast by Regions (2021-2025)
12.3 North America Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
12.4 Europe Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
12.6 South America Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Acute Myeloid Leukemia Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Acute Myeloid Leukemia by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Acute Myeloid Leukemia Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Acute Myeloid Leukemia Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Acute Myeloid Leukemia Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. GSK Corporate Information, Location and Competitors
Table 7. GSK Acute Myeloid Leukemia Major Business
Table 8. GSK Acute Myeloid Leukemia Total Revenue (USD Million) (2017-2018)
Table 9. GSK SWOT Analysis
Table 10. GSK Acute Myeloid Leukemia Product and Solutions
Table 11. GSK Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Eisai Corporate Information, Location and Competitors
Table 13. Eisai Acute Myeloid Leukemia Major Business
Table 14. Eisai Acute Myeloid Leukemia Total Revenue (USD Million) (2018-2019)
Table 15. Eisai SWOT Analysis
Table 16. Eisai Acute Myeloid Leukemia Product and Solutions
Table 17. Eisai Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 19. Bristol-Myers Squibb Acute Myeloid Leukemia Major Business
Table 20. Bristol-Myers Squibb Acute Myeloid Leukemia Total Revenue (USD Million) (2017-2018)
Table 21. Bristol-Myers Squibb SWOT Analysis
Table 22. Bristol-Myers Squibb Acute Myeloid Leukemia Product and Solutions
Table 23. Bristol-Myers Squibb Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Novartis Corporate Information, Location and Competitors
Table 25. Novartis Acute Myeloid Leukemia Major Business
Table 26. Novartis Acute Myeloid Leukemia Total Revenue (USD Million) (2017-2018)
Table 27. Novartis SWOT Analysis
Table 28. Novartis Acute Myeloid Leukemia Product and Solutions
Table 29. Novartis Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Daiichi Sankyo Corporate Information, Location and Competitors
Table 31. Daiichi Sankyo Acute Myeloid Leukemia Major Business
Table 32. Daiichi Sankyo Acute Myeloid Leukemia Total Revenue (USD Million) (2017-2018)
Table 33. Daiichi Sankyo SWOT Analysis
Table 34. Daiichi Sankyo Acute Myeloid Leukemia Product and Solutions
Table 35. Daiichi Sankyo Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Roche Corporate Information, Location and Competitors
Table 37. Roche Acute Myeloid Leukemia Major Business
Table 38. Roche Acute Myeloid Leukemia Total Revenue (USD Million) (2017-2018)
Table 39. Roche SWOT Analysis
Table 40. Roche Acute Myeloid Leukemia Product and Solutions
Table 41. Roche Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Sunesis Pharmaceuticals Corporate Information, Location and Competitors
Table 43. Sunesis Pharmaceuticals Acute Myeloid Leukemia Major Business
Table 44. Sunesis Pharmaceuticals Acute Myeloid Leukemia Total Revenue (USD Million) (2017-2018)
Table 45. Sunesis Pharmaceuticals SWOT Analysis
Table 46. Sunesis Pharmaceuticals Acute Myeloid Leukemia Product and Solutions
Table 47. Sunesis Pharmaceuticals Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Clavis Pharma ASA Corporate Information, Location and Competitors
Table 49. Clavis Pharma ASA Acute Myeloid Leukemia Major Business
Table 50. Clavis Pharma ASA Acute Myeloid Leukemia Total Revenue (USD Million) (2017-2018)
Table 51. Clavis Pharma ASA SWOT Analysis
Table 52. Clavis Pharma ASA Acute Myeloid Leukemia Product and Solutions
Table 53. Clavis Pharma ASA Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Celgene Corporate Information, Location and Competitors
Table 55. Celgene Acute Myeloid Leukemia Major Business
Table 56. Celgene Acute Myeloid Leukemia Total Revenue (USD Million) (2017-2018)
Table 57. Celgene SWOT Analysis
Table 58. Celgene Acute Myeloid Leukemia Product and Solutions
Table 59. Celgene Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Teva Corporate Information, Location and Competitors
Table 61. Teva Acute Myeloid Leukemia Major Business
Table 62. Teva Acute Myeloid Leukemia Total Revenue (USD Million) (2017-2018)
Table 63. Teva SWOT Analysis
Table 64. Teva Acute Myeloid Leukemia Product and Solutions
Table 65. Teva Acute Myeloid Leukemia Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Global Acute Myeloid Leukemia Revenue (Million USD) by Players (2015-2020)
Table 67. Global Acute Myeloid Leukemia Revenue Share by Players (2015-2020)
Table 68. Global Acute Myeloid Leukemia Revenue (Million USD) by Regions (2015-2020)
Table 69. Global Acute Myeloid Leukemia Revenue Market Share by Regions (2015-2020)
Table 70. North America Acute Myeloid Leukemia Revenue by Countries (2015-2020)
Table 71. North America Acute Myeloid Leukemia Revenue Market Share by Countries (2015-2020)
Table 72. Europe Acute Myeloid Leukemia Revenue (Million USD) by Countries (2015-2020)
Table 73. Asia-Pacific Acute Myeloid Leukemia Revenue (Million USD) by Countries (2015-2020)
Table 74. South America Acute Myeloid Leukemia Revenue by Countries (2015-2020)
Table 75. South America Acute Myeloid Leukemia Revenue Market Share by Countries (2015-2020)
Table 76. Middle East and Africa Acute Myeloid Leukemia Revenue (Million USD) by Countries (2015-2020)
Table 77. Middle East and Africa Acute Myeloid Leukemia Revenue Market Share by Countries (2015-2020)
Table 78. Global Acute Myeloid Leukemia Revenue (Million USD) by Type (2015-2020)
Table 79. Global Acute Myeloid Leukemia Revenue Share by Type (2015-2020)
Table 80. Global Acute Myeloid Leukemia Revenue Forecast by Type (2021-2025)
Table 81. Global Acute Myeloid Leukemia Revenue by Application (2015-2020)
Table 82. Global Acute Myeloid Leukemia Revenue Share by Application (2015-2020)
Table 83. Global Acute Myeloid Leukemia Revenue Forecast by Application (2021-2025)
Table 84. Global Acute Myeloid Leukemia Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Acute Myeloid Leukemia Picture
Figure 2. Global Acute Myeloid Leukemia Revenue Market Share by Type in 2019
Figure 3. Chemotherapy Picture
Figure 4. Targeted Therapy Picture
Figure 5. Acute Myeloid Leukemia Revenue Market Share by Application in 2019
Figure 6. Adults Picture
Figure 7. Children Picture
Figure 8. Global Acute Myeloid Leukemia Revenue (USD Million) and Growth Rate (2015-2025)
Figure 9. North America Acute Myeloid Leukemia Revenue (Million USD) and Growth Rate (2015-2025)
Figure 10. Europe Acute Myeloid Leukemia Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Asia-Pacific Acute Myeloid Leukemia Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. South America Acute Myeloid Leukemia Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Middle East and Africa Acute Myeloid Leukemia Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Global Acute Myeloid Leukemia Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Acute Myeloid Leukemia Revenue Share by Players in 2019
Figure 16. Global Top 5 Players Acute Myeloid Leukemia Revenue Market Share in 2019
Figure 17. Global Top 10 Players Acute Myeloid Leukemia Revenue Market Share in 2019
Figure 18. Key Players Market Share Trend
Figure 19. Global Acute Myeloid Leukemia Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 20. Global Acute Myeloid Leukemia Revenue Market Share by Regions (2015-2020)
Figure 21. Global Acute Myeloid Leukemia Revenue Market Share by Regions in 2018
Figure 22. North America Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 23. Europe Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 24. Asia-Pacific Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 25. South America Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 26. Middle East and Africa Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 27. North America Acute Myeloid Leukemia Revenue Market Share by Countries (2015-2020)
Figure 28. North America Acute Myeloid Leukemia Revenue Market Share by Countries in 2019
Figure 29. USA Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 30. Canada Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 31. Mexico Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 32. Europe Acute Myeloid Leukemia Revenue Market Share by Countries (2015-2020)
Figure 33. Europe Acute Myeloid Leukemia Revenue Market Share by Countries in 2019
Figure 34. Germany Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 35. UK Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 36. France Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 37. Russia Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 38. Italy Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 39. Asia-Pacific Acute Myeloid Leukemia Revenue Market Share by Countries (2015-2020)
Figure 40. Asia-Pacific Acute Myeloid Leukemia Revenue Market Share by Countries in 2019
Figure 41. China Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 42. Japan Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 43. Korea Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 44. India Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 45. Southeast Asia Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 46. South America Acute Myeloid Leukemia Revenue Market Share by Countries (2015-2020)
Figure 47. South America Acute Myeloid Leukemia Revenue Market Share by Countries in 2019
Figure 48. Brazil Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 49. Argentina Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 50. Middle East and Africa Acute Myeloid Leukemia Revenue Market Share by Countries (2015-2020)
Figure 51. Middle East and Africa Acute Myeloid Leukemia Revenue Market Share by Countries in 2019
Figure 52. Saudi Arabia Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 53. UAE Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 54. Egypt Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 55. South Africa Acute Myeloid Leukemia Revenue and Growth Rate (2015-2020)
Figure 56. Global Acute Myeloid Leukemia Revenue Share by Type (2015-2020)
Figure 57. Global Acute Myeloid Leukemia Revenue Share by Type in 2019
Figure 58. Global Acute Myeloid Leukemia Market Share Forecast by Type (2021-2025)
Figure 59. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 60. Global Targeted Therapy Revenue Growth Rate (2015-2020)
Figure 61. Global Acute Myeloid Leukemia Revenue Share by Application (2015-2020)
Figure 62. Global Acute Myeloid Leukemia Revenue Share by Application in 2019
Figure 63. Global Acute Myeloid Leukemia Market Share Forecast by Application (2021-2025)
Figure 64. Global Adults Revenue Growth Rate (2015-2020)
Figure 65. Global Children Revenue Growth Rate (2015-2020)
Figure 66. Global Acute Myeloid Leukemia Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 67. Global Acute Myeloid Leukemia Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 68. Global Acute Myeloid Leukemia Revenue Market Share Forecast by Regions (2021-2025)
Figure 69. North America Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
Figure 70. Europe Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
Figure 71. Asia-Pacific Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
Figure 72. South America Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
Figure 73. Middle East and Africa Acute Myeloid Leukemia Revenue Market Forecast (2021-2025)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel
急性骨髄性白血病治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Acute Myeloid Leukemia Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 7.6% in the forecast period of 2020 to 2025 and will expected to reach USD 774.8 million by 2025, from USD 578.1 million in 2019. The Acute…- T細胞急性リンパ性白血病治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global T-cell Acute Lymphoblastic Leukemia Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The…
- 急性リンパ性白血病治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Acute Lymphoid Leukemia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain o…
- 成人T細胞白血病/リンパ腫治療の世界市場 2020年：企業別・地域別・種類別・用途別市場予測 Market Overview The Adult T-Cell Leukemia/Lymphoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value …
- 慢性リンパ性白血病の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Chronic Lymphocytic Leukemia market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Chronic Lymphocy…